Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 11+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
1+ week, 4+ day ago (396+ words) Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place....
Nanosonics leans on trophon strength as CORIS moves toward commercial launch
2+ week, 6+ day ago (394+ words) Nanosonics has entered financial year 2027 with continued growth from its trophon disinfection business, while advancing the commercial rollout of its CORIS endoscope reprocessing platform and commencing a new on-market share buyback of up to $40 million. Revenue rose 3 per cent to…...
Dimerix banks payment from Everest as global licensing strategy gathers pace
3+ week, 4+ day ago (551+ words) Dimerix has received a US$10 million upfront payment from Everest Medicines under its commercial licensing agreement for its lead kidney disease candidate, DMX-200, adding further financial weight to the Melbourne biotechnology company’s push towards a pivotal Phase 3 readout. The payment, worth…...
Telix reports strong growth as late-stage cancer pipeline advances
3+ week, 4+ day ago (548+ words) Telix Pharmaceuticals reported a strong first half of 2026, with double-digit revenue growth and improved margins, supported by continued investment in a late-stage radiopharmaceutical pipeline advancing toward key clinical and regulatory milestones. The company generated revenue of US$477 million for the…...